Femoston Conti 1mg / 5mg, 28 tablets — Made in Netherlands — Free Delivery

Product description

Femoston® Conti tablets are used for the following indications:

• hormone replacement therapy (HRT) to eliminate symptoms caused by estrogen deficiency in women in the menopausal period, no earlier than 12 months after the last menstruation;
• prevention of osteoporosis in postmenopausal women with a high risk of fractures ("Femoston® Conti" should be used in patients only in case of intolerance or contraindications to the use of other drugs for the prevention of osteoporosis).

Compound

One tablet contains (active ingredients) micronized estradiol hemihydrate, which is equivalent to 1 mg of estradiol; dydrogesterone micronized 5 mg.

Excipients: lactose, monohydrate; hypromellose (HPMC 2910), corn starch, anhydrous colloidal silicon dioxide, magnesium stearate.

Film coating: mixed film coating Orange I (polyethylene glycol 400, hypromellose (HPMC 2910), iron oxide yellow (E172), iron oxide red (E172), titanium dioxide (E 171)).

Contraindications

• diagnosed in the past, present or suspected breast cancer;

Established or suspected estrogen-sensitive tumors (eg, endometrial cancer);

• vaginal bleeding of unknown origin;
• untreated endometrial hyperplasia;
• a history of active venous thromboembolism (deep vein thrombosis, pulmonary embolism);
• the presence of thrombophilic disorders (for example, a deficiency of protein C, protein S, or antithrombin);
• acute or recent thromboembolic arterial disease (eg angina pectoris, myocardial infarction);
• a history of acute liver disease or liver disease in which liver function tests have not returned to normal;
• porphyria;
• known hypersensitivity to active substances or to any of the excipients of the preparation.

Mode of application

Femoston® Conti is administered orally daily in accordance with the continuous combined regimen as described below.

Take one tablet daily for each 28-day cycle. Each blister is intended to be cured for 28 days. After that, you should immediately start a new cycle. These treatment cycles, which follow one after another, are continuous.

For the treatment of estrogen deficiency in postmenopausal women, the lowest effective dose should be taken as the starting and maintenance dose, and the duration of the treatment period should be as short as possible. Continuous combined treatment can be started with Femoston® Conti, depending on the time that has elapsed since the onset of menopause and the severity of symptoms. Women who naturally go through menopause can start treatment with the drug 12 months after their last menstrual period. Women who are menopausal as a result of surgery can start treatment immediately. The dose should be selected individually depending on the clinical response.

In women who are not using hormone replacement therapy, or in women switching from continuous combination hormone replacement therapy, treatment can be started on any convenient day. In women who are switching from cyclic or continuous sequential hormone replacement therapy, treatment should be started immediately the next day after the end of the previous cycle.

If a dose is missed, it should be taken as soon as possible. If more than 12 hours have passed, it is recommended to continue treatment with the next pill, without taking the missed pill. In such cases, a missed tablet may increase the likelihood of breakthrough bleeding or spotting.

The drug can be taken with or without food.

Application features

Pregnant

The drug is not indicated for use during pregnancy. If pregnancy occurs during treatment with Femoston® Conti, the drug should be discontinued immediately.

The drug is not indicated for use during breastfeeding.

Femoston® Conti is not indicated for use in women of reproductive age.

Children

The drug is not intended for use in children.

Drivers

The drug does not affect or has a slight effect on the ability to drive a car or operate machinery.

Overdose

Both estradiol and dydrogesterone are substances of low toxicity. In case of overdose, symptoms such as nausea, vomiting, breast tenderness, dizziness, abdominal pain, drowsiness / fatigue, and withdrawal bleeding may occur. Overdose is unlikely to require any specific or symptomatic treatment. The above information also applies to overdose cases in children.

Side effects

The most common adverse reactions in patients receiving estradiol / dydrogesterone therapy in clinical trials were headache, abdominal pain, breast pain / tenderness, and back pain.

Storage conditions

Store in its original packaging at a temperature not exceeding 30 ° C, out of the reach of children.

Shelf life is 3 years.